TST has been engaged in the hemophilia sector over 40 years, and led the revolution of hemophilia business model in the industry over decades. We continuously remain a significant share of 60% +/- at Factor VIII market by the end of 2016.

In March 2017, the distributor contract with previous principle (Bayer) was expired. At the following one year, TST initiated a series of strategic approaches and collaborative communications with potential partners who are in the hemophilia sector, and successfully entered a strategic partnership agreement with Sanofi. In November 2018, both parties signed contract and TST becomes the exclusive promotor of Sanofi’s hemophilia business covering the promotions of Eloctate and Alprolix, an extensive half-life recombinant Factor VIII and Factor IX for the treatment of hemophilia A and B patients respectively.

In Taiwan, the product formulary listing involves complicated administration processes and requires lengthy time, however, we pride ourselves on being agilely and efficiently in completing most hospital listings in a very short period. Based on IMS data, Eloctate quickly emerged from the market and captured more than 40% market share and has become market leader in Factor VIII in just one-year after product launch; and we will confidently keep growing at double digit in the 2nd year. This record high in terms of listing speed and market share achievement is an extremely high barrier and difficult for other players to follow.